COVID-19 vaccine makers Pfizer-BioNTech and Moderna are expanding their studies to children ages 5 to 11, according to The New York Times on Monday. According to information, the extension of the study aims to detect rare side effects such as inflammation of the heart, which occurred in vaccinated people under 30 years.
The FDA has asked Pfizer-BioNTech and Moderna to include 3.000 children in the age group of 5 to 11 years to investigate what is happening with these side effects mentioned above.
Pfizer told CNET that it began testing the COVID-19 vaccine in children ages 5 to 11 on June 8 and children under 5 on June 21. The study will include up to 4.500 participants from United States, Finland, Poland and Spain, according to Pfizer. Preliminary results for the 5 to 11 age group are expected in September and data for children aged 2 to 5 years, as well as 6 months to 2 years, later in the year.
Moderna began recruiting participants in March and has confirmed its expansion, according to the report.
Last week, the European Medicines Agency recommended the approval of the Moderna COVID-19 vaccine for children aged 12 to 17 years.
Source of information: cnet.com